S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
The Trade Desk: 3 reasons to buy before a new all-time high
Laser breakthrough could send stock soaring 2,467% (Ad)
Rivian shares gets discounted; shares can move lower 
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
The Trade Desk: 3 reasons to buy before a new all-time high
Laser breakthrough could send stock soaring 2,467% (Ad)
Rivian shares gets discounted; shares can move lower 
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
The Trade Desk: 3 reasons to buy before a new all-time high
Laser breakthrough could send stock soaring 2,467% (Ad)
Rivian shares gets discounted; shares can move lower 
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
The Trade Desk: 3 reasons to buy before a new all-time high
Laser breakthrough could send stock soaring 2,467% (Ad)
Rivian shares gets discounted; shares can move lower 
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
NASDAQ:KTTA

Pasithea Therapeutics (KTTA) Stock Price, News & Analysis

$7.20
-0.30 (-4.00%)
(As of 02/22/2024 ET)
Today's Range
$7.20
$7.70
50-Day Range
$5.60
$8.66
52-Week Range
$5.25
$17.40
Volume
8,834 shs
Average Volume
6,091 shs
Market Capitalization
$7.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00

Pasithea Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
455.6% Upside
$40.00 Price Target
Short Interest
Healthy
0.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.51 out of 5 stars


KTTA stock logo

About Pasithea Therapeutics Stock (NASDAQ:KTTA)

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

KTTA Stock Price History

KTTA Stock News Headlines

The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Pasithea Therapeutics' IND Application For PAS-004 Gets FDA Acceptance
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Pasithea Announces Positive In Vivo Preclinical Data For PAS-004
Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?
See More Headlines
Receive KTTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/22/2024
Next Earnings (Estimated)
2/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KTTA
Fax
N/A
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.00
High Stock Price Target
$40.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+455.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-13,940,000.00
Pretax Margin
-3,436.96%

Debt

Sales & Book Value

Annual Sales
$490,000.00
Book Value
$32.64 per share

Miscellaneous

Free Float
895,000
Market Cap
$7.49 million
Optionable
Not Optionable
Beta
0.78
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Lawrence Steinman BA (Age 76)
    M.D., Ph.D., Executive Chairman & Co-Founder
    Comp: $250k
  • Dr. Tiago Reis Marques M.D. (Age 47)
    Ph.D., CEO & Director
    Comp: $539.25k
  • Mr. Daniel H. Schneiderman (Age 46)
    Chief Financial Officer
    Comp: $327.91k
  • Dr. Yassine Bendiabdallah Ph.D. (Age 39)
    COO & Head of UK Clinics
  • Dr. Graeme Currie Ph.D.
    Chief Development Officer














KTTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Pasithea Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pasithea Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" KTTA shares.
View KTTA analyst ratings
or view top-rated stocks.

What is Pasithea Therapeutics' stock price target for 2024?

1 equities research analysts have issued 1 year price objectives for Pasithea Therapeutics' shares. Their KTTA share price targets range from $40.00 to $40.00. On average, they predict the company's share price to reach $40.00 in the next twelve months. This suggests a possible upside of 455.6% from the stock's current price.
View analysts price targets for KTTA
or view top-rated stocks among Wall Street analysts.

How have KTTA shares performed in 2024?

Pasithea Therapeutics' stock was trading at $7.40 at the beginning of 2024. Since then, KTTA stock has decreased by 2.7% and is now trading at $7.20.
View the best growth stocks for 2024 here
.

Are investors shorting Pasithea Therapeutics?

Pasithea Therapeutics saw a decrease in short interest during the month of January. As of January 31st, there was short interest totaling 9,300 shares, a decrease of 31.1% from the January 15th total of 13,500 shares. Based on an average daily trading volume, of 93,100 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.1% of the company's stock are short sold.
View Pasithea Therapeutics' Short Interest
.

When is Pasithea Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our KTTA earnings forecast
.

When did Pasithea Therapeutics' stock split?

Shares of Pasithea Therapeutics reverse split before market open on Tuesday, January 2nd 2024. The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Pasithea Therapeutics IPO?

(KTTA) raised $17 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 2,898,551 shares at a price of $5.00-$7.00 per share.

How do I buy shares of Pasithea Therapeutics?

Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KTTA) was last updated on 2/23/2024 by MarketBeat.com Staff